Illumina (NASDAQ:ILMN) Given New $90.00 Price Target at Robert W. Baird

Illumina (NASDAQ:ILMN) had its target price reduced by investment analysts at Robert W. Baird from $127.00 to $90.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the life sciences company’s stock. Robert W. Baird’s price target would indicate a potential upside of 6.02% from the stock’s current price.

Several other brokerages also recently weighed in on ILMN. UBS Group raised their price target on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Piper Sandler boosted their price target on Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a research note on Monday, February 10th. Hsbc Global Res cut Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. JPMorgan Chase & Co. boosted their target price on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Finally, Stephens raised their price target on shares of Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $149.25.

Illumina Stock Up 0.8 %

Shares of NASDAQ:ILMN opened at $84.89 on Wednesday. Illumina has a 12-month low of $80.18 and a 12-month high of $156.66. The stock has a market capitalization of $13.45 billion, a price-to-earnings ratio of -11.05, a PEG ratio of 1.60 and a beta of 1.17. The stock has a fifty day simple moving average of $121.35 and a two-hundred day simple moving average of $132.49. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, research analysts anticipate that Illumina will post 4.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Capital World Investors raised its stake in Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company’s stock worth $2,408,721,000 after acquiring an additional 14,481,232 shares during the period. Brown Advisory Inc. raised its position in shares of Illumina by 54,220.9% during the 4th quarter. Brown Advisory Inc. now owns 1,912,639 shares of the life sciences company’s stock valued at $255,586,000 after purchasing an additional 1,909,118 shares during the period. Norges Bank purchased a new position in shares of Illumina during the 4th quarter valued at $228,714,000. Bessemer Group Inc. boosted its holdings in Illumina by 32,837.5% in the 4th quarter. Bessemer Group Inc. now owns 1,348,131 shares of the life sciences company’s stock worth $180,152,000 after buying an additional 1,344,038 shares during the period. Finally, WCM Investment Management LLC increased its stake in Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock worth $551,625,000 after buying an additional 867,673 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.